Lutris Pharma Receives FDA Orphan Drug Designation for LUT014 for the Treatment of EGFRI-Induced Acneiform Rash
Published on 08/07/2025 at 18:05 | prnewswire.co.uk
View original content:https://www.prnewswire.co.uk/news-releases/lutris-pharma-receives-fda-orphan-drug-designation-for-lut014-for-the-treatment-of-egfri-induced-acneiform-rash-302073519.html
en | boerse | 67972267 |
